drugset / Trial / NCT00770172

G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy

NCT00770172

Phase 3 Completed 140 enrolled Centre Francois Baclesse
RandomizedOpen-labelSupportive care

Summary

RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy. It is not yet known which regimen of G-CSF may be more effective in preventing neutropenia. PURPOSE: This randomized phase III trial is comparing two different regimens of G-CSF to see how well it works in preventing persistent neutropenia in patients with solid tumors who are receiving chemotherapy.

Timeline

Start
2007-10
Primary completion
2011-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic Subcutaneous